Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community
Adam J. Nelson(Clinical Research Institute), Christopher B. Granger(Duke University), Vanita R. Aroda(Brigham and Women's Hospital), Melissa Magwire(Saint Luke's Health System), Jennifer B. Green, Rodica Pop‐Busui(University of Michigan), Jonathan Pak(Boehringer Ingelheim (United States)), Lisa A. Kaltenbach(Clinical Research Institute), Çağrı Şenyücel(Eli Lilly (United States)), Caroline R. Richardson, Julienne K. Kirk(Wake Forest University), Renato D. Lópes(Duke University), Hussein R. Al‐Khalidi(Clinical Research Institute), Darren K. McGuire, Monica C. Reed(Clinical Research Institute), Matthew A. Cavender, Emily C. O’Brien(Clinical Research Institute), Neha J. Pagidipati(Alnylam Pharmaceuticals (United States)), Ildiko Lingvay(Southwestern Medical Center), Laura Webb(Clinical Research Institute), Tanya Gaynor(Boehringer Ingelheim (United States))
Cited by 79
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|2.4k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k